Search

Nadine S Dejneka

from Eagleville, PA
Age ~54
Get Report
Related to:
Raphaela A Portorreal, 68Julia Dejneka, 93Arianna J Polanco, 25Tamara Dejneka, 83Victor Dejneka, 95Olga Dejneka, 86Ulyana R Bushnell, 55Victor J Dejneka, 52
Connected to:
Stephen E Dejniak, 40Jacob Dejno, 35Stephania L Dejno, 48David A Dejnozka, 49Julio A Dejo, 45Linda Dejo, 57Sabrina S Dejoannis, 50Brandon J Dejohn, 52Joseph A Dejohn, 59Julia M Dejohn, 27

Nadine Dejneka Phones & Addresses

  • 2313 Lexington Ct, Norristown, PA 19403 (610) 630-1842
  • Eagleville, PA
  • 27 Fairview Rd, Skillman, NJ 08558 (609) 466-2432
  • 3300 191St St, Aventura, FL 33180 (305) 466-6922
  • Miami, FL
  • 200 Wynnewood Ave, Wynnewood, PA 19096 (610) 658-6258
  • Hershey, PA

Work

Position: Principal scientist

Resumes

Resumes

Nadine Dejneka Photo 1

Principal Scientist

View page
Location:
2313 Lexington Ct, Eagleville, PA 19403
Work:

Principal Scientist

Publications

Us Patents

Compositions And Methods For Selective Inhibition Of Vegf

View page
US Patent:
8470792, Jun 25, 2013
Filed:
Dec 4, 2009
Appl. No.:
12/631078
Inventors:
Phillip Frost - Miami Beach FL, US
Nadine Dejneka - Wynnewood PA, US
Ottrina S. Bond - Aventura FL, US
Naveed Shams - Danville CA, US
Assignee:
Opko Pharmaceuticals, LLC. - Miami FL
International Classification:
C12N 15/11
A61K 48/00
C07H 21/02
C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.

Compositions And Methods For Regulating Complement System

View page
US Patent:
20070178068, Aug 2, 2007
Filed:
Dec 22, 2006
Appl. No.:
11/615554
Inventors:
Samuel Reich - Merion Station PA, US
Nadine Dejneka - Wynnewood PA, US
International Classification:
A61K 48/00
C07H 21/02
A61K 9/127
US Classification:
424093200, 514044000, 514081000, 424450000, 536023100
Abstract:
The disclosure provided herein provides for methods and compositions for modulating the human complement pathway by reducing the expression or production of one or more complement pathway protein and uses for such methods for treating diseases including ocular disease and macular degeneration related disease. The invention also includes active agents for mediating the modulation of the complement pathway including siRNA designed to cause the RNAi-mediated degradation of complement pathway proteins.

Compositions And Methods For Inhibition Of Vegf

View page
US Patent:
20110142915, Jun 16, 2011
Filed:
Dec 6, 2010
Appl. No.:
12/960933
Inventors:
Nadine Dejneka - Wynnewood PA, US
Assignee:
OPKO OPHTHALMICS, LLC - Miami FL
International Classification:
A61K 39/395
C07H 21/02
A61K 31/713
A61K 33/24
A61K 9/127
A61P 35/00
A61P 29/00
A61P 3/10
US Classification:
424450, 536 245, 514 44 A, 424649, 4241451
Abstract:
Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.

Compositions And Methods For Inhibition Of Vegf

View page
US Patent:
20130039971, Feb 14, 2013
Filed:
Jul 23, 2012
Appl. No.:
13/555836
Inventors:
Nadine Dejneka - Wynnewood PA, US
Assignee:
OPKO OPHTHALMICS, LLC - Miami FL
International Classification:
A61K 31/713
A61P 35/00
A61P 9/10
A61P 27/02
A61N 5/10
A61P 17/06
A61P 19/02
A61K 33/24
A61K 9/127
A61K 39/395
C07H 21/02
A61P 29/00
US Classification:
424450, 536 245, 514 44 A, 424649, 514 34, 4241431, 424 932, 600 1
Abstract:
Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.

Method Of Modulating Müller Glia Cells

View page
US Patent:
20180344777, Dec 6, 2018
Filed:
May 24, 2018
Appl. No.:
15/988821
Inventors:
- Horsham PA, US
Nadine S. Dejneka - Spring House PA, US
Assignee:
Janssen Biotech, Inc. - Horsham PA
International Classification:
A61K 35/51
A61P 27/00
A61P 25/00
A61K 35/30
Abstract:
Methods and compositions for treating ophthalmic disease, in particular retinal degeneration, including modulating Müller glia, restoring retinal synaptic connectivity and forming α2δ1-containing synapses, using postpartum-derived cells are disclosed.

Methods Of Obtaining Cells From Human Postpartum Umbilical Cord Arterial Tissue

View page
US Patent:
20180346874, Dec 6, 2018
Filed:
May 24, 2018
Appl. No.:
15/988782
Inventors:
- Horsham PA, US
Nadine S. Dejneka - Spring House PA, US
Assignee:
Janssen Biotech, Inc. - Horsham PA
International Classification:
C12N 5/073
A61K 35/51
Abstract:
The invention provides for methods of obtaining cells from mammalian, preferably human, postpartum umbilical cord arterial tissue and use of these cells to treat ocular degenerative conditions. In particular, methods of the invention result in the isolation of a homogenous population of human postpartum umbilical cord arterial tissue-derived cells. In certain embodiments, the cells: express CD13, CD90, NG2, and HLA-ABC; do not express one or more of CD31, CD34, CD45, CD117, FSP1, and E-cadherin. In other embodiments, the cells secrete one or more of thrombospondin-1, BDNF and sVEGFR1.

Treatment Of Retinal Degeneration Using Progenitor Cells

View page
US Patent:
20180327713, Nov 15, 2018
Filed:
Jul 19, 2018
Appl. No.:
16/040350
Inventors:
- HORSHAM PA, US
JING CAO - SPRING HOUSE PA, US
NADINE DEJNEKA - SPRING HOUSE PA, US
Assignee:
JANSSEN BIOTECH, INC. - HORSHAM PA
International Classification:
C12N 5/073
C12N 5/079
A61P 27/02
A61K 35/51
A61K 9/00
Abstract:
Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Trophic factors and other agents secreted by the progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells such as photoreceptor cells are also disclosed.

Treatment Of Retinal Vascular Disease Using Progenitor Cells

View page
US Patent:
20180015129, Jan 18, 2018
Filed:
Jun 28, 2017
Appl. No.:
15/636140
Inventors:
- Horsham PA, US
Nadine Dejneka - Spring House PA, US
Assignee:
Janssen Biotech, Inc. - Horsham PA
International Classification:
A61K 9/00
Abstract:
Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.
Control profile
Nadine S Dejneka from Eagleville, PA, age ~54 Get Report